197 related articles for article (PubMed ID: 26325626)
1. Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.
Capulli M; Maurizi A; Ventura L; Rucci N; Teti A
Mol Ther Nucleic Acids; 2015 Sep; 4(9):e248. PubMed ID: 26325626
[TBL] [Abstract][Full Text] [Related]
2. Chloroquine increases osteoclast activity in vitro but does not improve the osteopetrotic bone phenotype of ADO2 mice.
Alam I; Gerard-O'Riley RL; Acton D; Hardman SL; Hong JM; Bruzzaniti A; Econs MJ
Bone; 2021 Dec; 153():116160. PubMed ID: 34464779
[TBL] [Abstract][Full Text] [Related]
3. Effect of Allele-Specific Clcn7
Saffie-Siebert S; Alam I; Sutera FM; Dehsorkhi A; Torabi-Pour N; Baran-Rachwalska P; Iamartino L; Teti A; Maurizi A; Gerard-O'Riley RL; Acton D; Econs MJ
Calcif Tissue Int; 2024 Jul; 115(1):85-96. PubMed ID: 38733412
[TBL] [Abstract][Full Text] [Related]
4. RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development.
Maurizi A; Capulli M; Patel R; Curle A; Rucci N; Teti A
Bone; 2018 May; 110():343-354. PubMed ID: 29501587
[TBL] [Abstract][Full Text] [Related]
5. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II.
Waguespack SG; Koller DL; White KE; Fishburn T; Carn G; Buckwalter KA; Johnson M; Kocisko M; Evans WE; Foroud T; Econs MJ
J Bone Miner Res; 2003 Aug; 18(8):1513-8. PubMed ID: 12929941
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic severity of autosomal dominant osteopetrosis type II (ADO2) mice on different genetic backgrounds recapitulates the features of human disease.
Alam I; McQueen AK; Acton D; Reilly AM; Gerard-O'Riley RL; Oakes DK; Kasipathi C; Huffer A; Wright WB; Econs MJ
Bone; 2017 Jan; 94():34-41. PubMed ID: 27746321
[TBL] [Abstract][Full Text] [Related]
7. Effect of Roflumilast, a Selective PDE4 Inhibitor, on Bone Phenotypes in ADO2 Mice.
Alam I; Hardman SL; Gerard-O'Riley RL; Acton D; Parker RS; Hong JM; Bruzzaniti A; Econs MJ
Calcif Tissue Int; 2024 Apr; 114(4):419-429. PubMed ID: 38300304
[TBL] [Abstract][Full Text] [Related]
8. Novel hybrid silicon-lipid nanoparticles deliver a siRNA to cure autosomal dominant osteopetrosis in mice. Implications for gene therapy in humans.
Maurizi A; Patrizii P; Teti A; Sutera FM; Baran-Rachwalska P; Burns C; Nandi U; Welsh M; Torabi-Pour N; Dehsorkhi A; Saffie-Siebert S
Mol Ther Nucleic Acids; 2023 Sep; 33():925-937. PubMed ID: 37680985
[TBL] [Abstract][Full Text] [Related]
9. Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models.
Alam I; Gray AK; Chu K; Ichikawa S; Mohammad KS; Capannolo M; Capulli M; Maurizi A; Muraca M; Teti A; Econs MJ; Del Fattore A
Bone; 2014 Feb; 59():66-75. PubMed ID: 24185277
[TBL] [Abstract][Full Text] [Related]
10. Clcn7
Caetano-Lopes J; Lessard SG; Hann S; Espinoza K; Kang KS; Lim KE; Horan DJ; Noonan HR; Hu D; Baron R; Robling AG; Warman ML
Bone; 2017 Dec; 105():253-261. PubMed ID: 28942122
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow transplantation as a therapy for autosomal dominant osteopetrosis type 2 in mice.
Alam I; Gerard-O'Riley RL; Acton D; Hardman SL; Murphy M; Alvarez MB; Blosser RJ; Sinn A; Srour EF; Kacena MA; Econs MJ
FASEB J; 2022 Sep; 36(9):e22471. PubMed ID: 35959867
[TBL] [Abstract][Full Text] [Related]
12. CLCN7, a gene shared by autosomal recessive and autosomal dominant osteopetrosis.
Stauber T; Wartosch L; Vishnolia S; Schulz A; Kornak U
Bone; 2023 Mar; 168():116639. PubMed ID: 36513280
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical implications.
Norwood I; Szondi D; Ciocca M; Coudert A; Cohen-Solal M; Rucci N; Teti A; Maurizi A
Bone; 2021 Mar; 144():115828. PubMed ID: 33359007
[TBL] [Abstract][Full Text] [Related]
14. Extra-skeletal manifestations in mice affected by
Maurizi A; Capulli M; Curle A; Patel R; Ucci A; Côrtes JA; Oxford H; Lamandé SR; Bateman JF; Rucci N; Teti A
Bone Res; 2019; 7():17. PubMed ID: 31231577
[TBL] [Abstract][Full Text] [Related]
15. Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in
Chen X; Zhang K; Hock J; Wang C; Yu X
Bone Res; 2016; 4():16035. PubMed ID: 27990310
[TBL] [Abstract][Full Text] [Related]
16. The PDE4 Inhibitors Roflumilast and Rolipram Rescue ADO2 Osteoclast Resorption Dysfunction.
Hong JM; Gerard-O'Riley RL; Acton D; Alam I; Econs MJ; Bruzzaniti A
Calcif Tissue Int; 2024 Apr; 114(4):430-443. PubMed ID: 38483547
[TBL] [Abstract][Full Text] [Related]
17. ClC-7 Regulates the Pattern and Early Development of Craniofacial Bone and Tooth.
Zhang Y; Ji D; Li L; Yang S; Zhang H; Duan X
Theranostics; 2019; 9(5):1387-1400. PubMed ID: 30867839
[TBL] [Abstract][Full Text] [Related]
18. ClC-7 expression levels critically regulate bone turnover, but not gastric acid secretion.
Supanchart C; Wartosch L; Schlack C; Kühnisch J; Felsenberg D; Fuhrmann JC; de Vernejoul MC; Jentsch TJ; Kornak U
Bone; 2014 Jan; 58():92-102. PubMed ID: 24103576
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of ClC7 Cl- channels and their inhibition in mutant (G215R) associated with autosomal dominant osteopetrosis type II in native osteoclasts and hClcn7 gene-expressing cells.
Kajiya H; Okamoto F; Ohgi K; Nakao A; Fukushima H; Okabe K
Pflugers Arch; 2009 Oct; 458(6):1049-59. PubMed ID: 19543743
[TBL] [Abstract][Full Text] [Related]
20. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
Chu K; Snyder R; Econs MJ
J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
